| Literature DB >> 35850582 |
Zichen Wang1,2, Luming Zhang1,3, Shaojin Li4, Fengshuo Xu3, Didi Han3, Hao Wang5, Tao Huang3, Haiyan Yin6, Jun Lyu7,8.
Abstract
BACKGROUND: Sepsis still threatens the lives of more than 300 million patients annually and elderly patients with sepsis usually have a more complicated condition and a worse prognosis. Existing studies have shown that both Hematocrit (HCT) and albumin (ALB) can be used as potential predictors of sepsis, and their difference HCT-ALB has a significant capacity to diagnose infectious diseases. Currently, there is no relevant research on the relationship between HCT-ALB and the prognosis of elderly sepsis patients. Therefore, this study aims to explore the association between HCT-ALB and mortality in elderly patients with sepsis.Entities:
Keywords: Elderly; HCT-ALB; Mortality; Multi-center; Sepsis
Mesh:
Substances:
Year: 2022 PMID: 35850582 PMCID: PMC9295343 DOI: 10.1186/s12879-022-07609-7
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.667
Fig. 1Inclusion and Exclusion Flowchart of the Study
Fig. 2The result of optimal cut-off value calculated by Youden Index. a Receiver operating characteristic (ROC) curve for HCT-ALB. The black point represented the position of optimal point in ROC curve where sensitivity was 0.496 and specificity was 0.631. b The relationship between HCT-ALB and the position of max Youden Index. The black point represented the position of optimal cut-off value and the related Youden Index. The optimal cut-off point of HCT-ALB was 6.7; The max Youden Index was 0.127
The Baseline clinical characteristics of eICU-CRD and MIMIC-IV patients
| eICU-CRD | MIMIC-IV | |||||||
|---|---|---|---|---|---|---|---|---|
| Total (n = 16127) | HCT-ALB < 6.7 (n = 9899) | HCT-ALB ≥ 6.7 (n = 6238) | P value | Total (n = 3043) | HCT-ALB < 6.7 (n = 1970) | HCT-ALB ≥ 6.7 (n = 1073) | P value | |
| Age | 76 (70,83) | 76 (70,83) | 76 (70,83) | 0.532 | 75 (69,82) | 75 (69, 81) | 76 (70, 82) | 0.048 |
| HCT (%) | 30.8 (27.0,35.4) | 28. (25.7,32.6) | 34.3 (30.4,38.8) | < 0.001 | 32.0 (27.6,36.3) | 29.7 (25.9, 33.5) | 36.3 (32.9, 40.1) | < 0.001 |
| ALB (g/L) | 27.0 (22.0,32.0) | 29.0 (25.0,34.0) | 22.0 (19.0,26.0) | < 0.001 | 28.0 (24.0,32.0) | 30.0 (26.0, 34.0) | 24.0 (21.0, 28.0) | < 0.001 |
| SOFA | 7 (5,9) | 7 (5,9) | 7 (5,9) | < 0.001 | 7 (5,10) | 7 (4, 10) | 8 (5, 11) | < 0.001 |
| Gender (%) | 0.010 | 0.445 | ||||||
| Male | 8607 (53.4) | 5198 (52.6) | 3409 (54.6) | 1686 (55.4) | 1102 (55.9) | 584 (54.4) | ||
| Female | 7520 (46.6) | 4691 (47.4) | 2829 (45.4) | 1357 (44.6) | 868 (44.1) | 489 (45.6) | ||
| BMI (%) | < 0.001 | 0.322 | ||||||
| Underweight | 828 (5.1) | 449 (4.5) | 379 (6.1) | 154 (5.1) | 89 (4.5) | 65 (6.1) | ||
| Normalweight | 5110 (31.7) | 3022 (30.6) | 2088 (33.5) | 965 (31.7) | 628 (31.9) | 337 (31.4) | ||
| Overweight | 4520 (28.0) | 2843 (28.7) | 1677 (26.9) | 876 (28.8) | 573 (29.1) | 303 (28.2) | ||
| Obese | 5669 (35.2) | 3575 (36.2) | 2094 (33.6) | 1048 (34.4) | 680 (34.5) | 368 (34.3) | ||
| Ventilation (%) | < 0.001 | 0.001 | ||||||
| No | 11,202 (69.5) | 7061 (71.4) | 4141 (66.4) | 356 (11.7) | 259 (13.1) | 97 (9.0) | ||
| Yes | 4925 (30.5) | 2828 (28.6) | 2097 (33.6) | 2687 (88.3) | 1711 (86.9) | 976 (91.0) | ||
| Dialysis (%) | < 0.001 | 0.712 | ||||||
| No | 14,389 (89.7) | 8656 (87.4) | 5743 (92.1) | 2724 (89.5) | 1760 (89.3) | 964 (89.8) | ||
| Yes | 1738 (10.3) | 1243 (12.6) | 495 (7.9) | 319 (10.5) | 210 (10.7) | 109 (10.2) | ||
| Vasopressor (%) | < 0.001 | < 0.001 | ||||||
| No | 11,271 (69.9) | 7205 (72.8) | 4066 (65.2) | 1218 (40.0) | 859 (43.6) | 359 (33.5) | ||
| Yes | 4856 (30.1) | 2684 (27.2) | 2172 (34.8) | 1825 (60.0) | 1111 (56.4) | 714 (66.5) | ||
| Congestive heart Failure | < 0.001 | 0.040 | ||||||
| No | 12,162 (75.4) | 7310 (73.9) | 4852 (77.8) | 1712 (56.3) | 1081 (54.9) | 631 (58.8) | ||
| Yes | 3965 (24.6) | 2579 (26.1) | 1386 (22.2) | 1331 (43.7) | 889 (45.1) | 442 (41.2) | ||
| Chronic pulmonary disease (%) | 0.941 | 0.450 | ||||||
| No | 12,804 (79.4) | 7849 (79.4) | 4955 (79.4) | 2108 (69.3) | 1355 (68.8) | 753 (70.2) | ||
| Yes | 3323 (20.6) | 2040 (20.6) | 1283 (20.6) | 935 (30.7) | 615 (31.2) | 320 (29.8) | ||
| Diabetes (%) | < 0.001 | 0.001 | ||||||
| No | 13,409 (83.1) | 8097 (81.9) | 5312 (85.2) | 1923 (63.2) | 1204 (61.1) | 719 (67.0) | ||
| Yes | 2718 (16.9) | 1792 (18.1) | 926 (14.8) | 1120 (36.8) | 766 (38.9) | 354 (33.0) | ||
| Renal disease (%) | < 0.001 | < 0.001 | ||||||
| No | 14,669 (91.0) | 8867 (89.7) | 5802 (93.0) | 2025 (66.5) | 1240 (62.9) | 785 (73.2) | ||
| Yes | 1458 (9.0) | 1022 (10.3) | 436 (7.0) | 1018 (33.5) | 730 (37.1) | 288 (26.8) | ||
| Malignant cancer (%) | 0.314 | 0.006 | ||||||
| No | 12,699 (78.7) | 7761 (78.5) | 4938 (79.2) | 2428 (79.8) | 1542 (78.3) | 886 (82.6) | ||
| Yes | 3428 (21.3) | 2128 (21.5) | 1300 (20.8) | 615 (20.2) | 428 (21.7) | 187 (17.4) | ||
| Liver disease (%) | < 0.001 | 0.271 | ||||||
| No | 15,352 (95.2) | 9,461 (95.7) | 5891 (94.4) | 2586 (85.0) | 1685 (85.5) | 901 (84.0) | ||
| Yes | 775 (4.8) | 428 (4.3) | 347 (5.6) | 457 (15.0) | 285 (14.5) | 172 (16.0) | ||
| Metastatic solid tumor (%) | 0.069 | 0.247 | ||||||
| No | 15,591 (96.7) | 9,581 (96.9) | 6010 (96.3) | 2779 (91.3) | 1790 (90.9) | 989 (92.2) | ||
| Yes | 536 (3.3) | 308 (3.1) | 228 (3.7) | 264 (8.7) | 180 (9.1) | 84 (7.8) | ||
| ICU mortality (%) | < 0.001 | < 0.001 | ||||||
| No | 13,899 (86.2) | 8766 (88.6) | 5133 (82.3) | 2377 (78.1) | 1601 (81.3) | 776 (72.3) | ||
| Yes | 2228 (13.8) | 1123 (11.4) | 1105 (17.7) | 666 (21.9) | 369 (18.7) | 297 (27.7) | ||
| Hospital mortality (%) | < 0.001 | < 0.001 | ||||||
| No | 12,585 (78.0) | 8128 (82.2) | 4457 (71.4) | 2065 (67.9) | 1391 (70.6) | 674 (62.8) | ||
| Yes | 3542 (22.0) | 1761 (17.8) | 1781 (28.6) | 978 (32.1) | 579 (29.4) | 399 (37.2) | ||
Continuous variables were expressed by median (interquartile), categorical variables were expressed by count (percentage)
P values were calculated to compare difference between HCT-ALB groups for each dataset separately
Analysis for association between HCT-ALB group and outcomes
| ICU mortality | Hospital mortality | |||
|---|---|---|---|---|
| OR (95% CI) | P value | OR (95% CI) | P value | |
| eICU-CRD | ||||
| Univariable model | 1.68 (1.54, 1.84) | < 0.001 | 1.84 (1.71, 1.99) | < 0.001 |
| Multivariable model | 1.50 (1.36, 1.65) | < 0.001 | 1.71 (1.58, 1.87) | < 0.001 |
| MIMIC-IV | ||||
| Univariable model | 1.66 (1.39, 1.98) | < 0.001 | 1.42 (1.22, 1.66) | < 0.001 |
| Multivariable model | 1.41 (1.15, 1.72) | 0.001 | 1.27 (1.07, 1.51) | 0.007 |
Multivariate models were adjusted by Age, Gender, BMI group, SOFA score, Ventilation, Dialysis, Vasopressor use, Comorbidities (CHF, Chronic Pulmonary Disease, Diabetes, Renal disease, Malignant cancer, Liver disease, and Metastatic solid tumor), excluding models belonging subgroup variate
OR odds ratio, CI confidence interval
The OR (95CI%) were calculated when low HCT-ALB (< 6.7) groups set as reference
Subgroup analysis for association between HCT-ALB group and outcomes for eICU-CRD
| ICU mortality | Hospital mortality | ||||||
|---|---|---|---|---|---|---|---|
| Subgroups | N | OR (95%CI) | P value | P—interaction | OR (95%CI) | P value | P—interaction |
| Total | 16,127 | 1.50 (1.36, 1.65) | < 0.001 | / | 1.71 (1.58, 1.87) | < 0.001 | / |
| Age | 0.390 | 0.861 | |||||
| 65–80 | 10,624 | 1.60 (1.41, 1.80) | < 0.001 | 1.76 (1.59, 1.96) | < 0.001 | ||
| > 80 | 5503 | 1.43 (1.22, 1.69) | < 0.001 | 1.73 (1.52, 1.98) | < 0.001 | ||
| Gender | 0.353 | 0.208 | |||||
| Male | 8607 | 1.43 (1.25, 1.64) | < 0.001 | 1.63 (1.46, 1.83) | < 0.001 | ||
| Female | 7052 | 1.57 (1.36, 1.82) | < 0.001 | 1.82 (1.62, 2.06) | < 0.001 | ||
| SOFA | 0.064 | 0.040 | |||||
| < 6 | 5592 | 1.65 (1.29, 2.11) | < 0.001 | 1.89 (1.59, 2.26) | < 0.001 | ||
| ≥ 6 | 10,535 | 1.50 (1.30, 1.67) | < 0.001 | 1.70 (1.55, 1.68) | < 0.001 | ||
| BMI | 0.324 | 0.658 | |||||
| Underweight | 828 | 1.93 (1.29, 2.91) | 0.001 | 1.86 (1.35, 2.61) | < 0.001 | ||
| Normalweight | 5110 | 1.55 (0.68, 3.60) | 0.299 | 2.00 (1.13, 3.56) | 0.017 | ||
| Overweight | 4520 | 1.78 (0.95, 3.35) | 0.007 | 2.32 (1.51, 3.95) | < 0.001 | ||
| Obese | 5669 | 1.91 (1.20, 3.02) | 0.006 | 2.01 (1.45, 2.78) | < 0.001 | ||
| Congestive heart failure | 0.809 | 0.499 | |||||
| No | 12,162 | 1.48 (1.32, 1.66) | < 0.001 | 1.69 (1.54, 1.86) | < 0.001 | ||
| Yes | 3965 | 1.54 (1.27, 1.88) | < 0.001 | 1.81 (1.54, 2.14) | < 0.001 | ||
| Chronic pulmonary disease | 0.753 | 0.262 | |||||
| No | 12,804 | 1.49 (1.33, 1.69) | < 0.001 | 1.68 (1.53, 1.85) | < 0.001 | ||
| Yes | 3323 | 1.56 (1.26, 1.94) | < 0.001 | 1.87 (1.56, 2.23) | < 0.001 | ||
| Diabetes | 0.577 | 0.621 | |||||
| No | 13,409 | 1.54 (1.39, 1.72) | < 0.001 | 1.73 (1.53, 1.89) | < 0.001 | ||
| Yes | 2718 | 1.66 (1.33, 2.05) | < 0.001 | 1.72 (1.38, 2.13) | < 0.001 | ||
| Renal disease | 0.387 | 0.206 | |||||
| No | 14,669 | 1.49 (1.34, 1.65) | < 0.001 | 1.70 (1.56, 1.85) | < 0.001 | ||
| Yes | 1458 | 1.65 (1.17, 2.32) | < 0.001 | 1.99 (1.50, 2.66) | < 0.001 | ||
| Malignant cancer | 0.984 | 0.721 | |||||
| No | 12,699 | 1.49 (1.34, 1.67) | < 0.001 | 1.71 (1.55, 1.88) | < 0.001 | ||
| Yes | 3428 | 1.47 (1.21, 1.81) | < 0.001 | 1.76 (1.49, 2.09) | < 0.001 | ||
| Liver disease | 0.735 | 0.435 | |||||
| No | 15,352 | 1.50 (1.36, 1.67) | < 0.001 | 1.71 (1.57, 1.86) | < 0.001 | ||
| Yes | 775 | 1.39 (0.97, 2.01) | 0.073 | 1.99 (1.44, 1.78) | < 0.001 | ||
| Metastatic solid tumor | 0.953 | 0.324 | |||||
| No | 15,591 | 1.50 (1.35, 1.66) | < 0.001 | 1.70 (1.57,1.86) | < 0.001 | ||
| Yes | 536 | 1.51 (0.92, 2.48) | 0.104 | 2.21 (1.47, 3.34) | < 0.001 | ||
Multivariate models were adjusted by Age, Gender, BMI group, SOFA score, Ventilation, Dialysis, Vasopressor use, Comorbidities (CHF, Chronic Pulmonary Disease, Diabetes, Renal disease, Malignant cancer, Liver disease, and Metastatic solid tumor), excluding models belonging subgroup variate
BMI subgroup were defined as underweight (BMI < 18.5 kg/m2), normal weight (18.5–24.9 kg/m2), overweight (25.0–29.9 kg/m2), and obese (≥ 30.0 kg/m2)
OR odds ratio, CI confidence interval
The OR (95CI%) were calculated when low HCT-ALB (< 6.7) groups set as reference
Subgroup analysis for association between HCT-ALB group and outcomes for MIMIC-IV
| ICU mortality | Hospital mortality | ||||||
|---|---|---|---|---|---|---|---|
| Subgroups | N | OR (95%CI) | P value | P—interaction | OR (95%CI) | P value | P—interaction |
| Total | 3043 | 1.41 (1.15, 1.72) | 0.001 | / | 1.26 (1.07, 1.51) | 0.007 | / |
| Age | 0.707 | 0.438 | |||||
| 65–80 | 2156 | 1.61 (1.27, 2.05) | < 0.001 | 1.43 (1.15, 1.746) | 0.001 | ||
| > 80 | 887 | 1.14 (0.79, 1.64) | 0.473 | 1.01 (0.73, 1.38) | 0.964 | ||
| Gender | 0.189 | 0.051 | |||||
| Male | 1686 | 1.28 (0.97, 1.68) | 0.075 | 1.09 (0.86, 1.38) | 0.488 | ||
| Female | 1357 | 1.64 (1.21, 2.22) | 0.001 | 1.54 (1.20, 1.99) | 0.001 | ||
| SOFA | 0.433 | 0.446 | |||||
| < 6 | 994 | 2.37 (1.37, 4.10) | 0.002 | 1.56 (1.07, 2.24) | 0.018 | ||
| ≥ 6 | 2049 | 1.39 (1.12, 1.71) | 0.002 | 1.25 (1.03, 1.52) | 0.022 | ||
| BMI | 0.683 | 0.405 | |||||
| Underweight | 154 | 1.03 (0.35, 2.94) | 0.954 | 1.01 (0.42, 2.39) | 0.986 | ||
| Normalweight | 965 | 8.94 (1.55, 73.6) | 0.021 | 2.72 (1.01, 7.25) | 0.044 | ||
| Overweight | 876 | 8.20 (1.51, 58.6) | 0.018 | 2.32 (0.94, 5.69) | 0.065 | ||
| Obese | 1048 | 1.23 (0.43, 3.36) | 0.689 | 0.84 (0.42, 1.61) | 0.609 | ||
| Congestive heart failure | 0.302 | 0.214 | |||||
| No | 1712 | 1.25 (0.94, 1.65) | 0.119 | 1.13 (0.89, 1.42) | 0.324 | ||
| Yes | 1331 | 1.62 (1.21, 2.18) | 0.001 | 1.46 (1.12, 1.89) | 0.005 | ||
| Chronic pulmonary disease | 0.395 | 0.623 | |||||
| No | 2108 | 1.49 (1.16, 1.91) | 0.002 | 1.31 (1.06, 1.61) | 0.013 | ||
| Yes | 935 | 1.28 (0.90, 1.82) | 0.162 | 1.20 (0.88, 1.64) | 0.254 | ||
| Diabetes | 0.226 | 0.136 | |||||
| No | 1923 | 1.28 (0.99, 1.64) | 0.056 | 1.14 (0.92, 1.42) | 0.214 | ||
| Yes | 1120 | 1.75 (1.24, 2.46) | 0.001 | 1.54 (1.15, 2.07) | 0.004 | ||
| Renal disease | 0.401 | 0.269 | |||||
| No | 2025 | 1.32 (1.03, 1.70) | 0.027 | 1.16 (0.94, 1.45) | 0.179 | ||
| Yes | 1018 | 1.60 (1.13, 2.26) | 0.008 | 1.47 (1.09, 1.98) | 0.012 | ||
| Malignant cancer | 0.758 | 0.072 | |||||
| No | 2428 | 1.47 (1.17, 1.84) | < 0.001 | 1.39 (1.15, 1.69) | < 0.001 | ||
| Yes | 615 | 1.41 (0.88, 2.24) | 0.148 | 0.925 (0.61, 1.39) | 0.713 | ||
| Liver disease | 0.362 | 0.554 | |||||
| No | 2586 | 1.39 (1.11, 1.73) | 0.004 | 1.25 (1.03, 1.51) | 0.027 | ||
| Yes | 457 | 1.73 (1.05, 2.87) | 0.031 | 1.46 (0.94, 2.26) | 0.091 | ||
| Metastatic solid tumor | 0.639 | 0.875 | |||||
| No | 2779 | 1.44 (1.17, 1.79) | < 0.001 | 1.28 (1.06, 1.53) | 0.009 | ||
| Yes | 264 | 1.28 (0.65, 2.50) | 0.464 | 1.36 (0.73, 2.52) | 0.328 | ||
Multivariate models were adjusted by Age, Gender, BMI group, SOFA score, Ventilation, Dialysis, Vasopressor use, Comorbidities (CHF, Chronic Pulmonary Disease, Diabetes, Renal disease, Malignant cancer, Liver disease, and Metastatic solid tumor), excluding models belonging subgroup variate
BMI subgroup were defined as underweight (BMI < 18.5 kg/m2), normal weight (18.5–24.9 kg/m2), overweight (25.0–29.9 kg/m2), and obese (≥ 30.0 kg/m2)
OR odds ratio, CI confidence interval
The OR (95CI%) were calculated when low HCT-ALB (< 6.7) groups set as reference